STOCK TITAN

Liminal Biosciences Inc - LMNL STOCK NEWS

Welcome to our dedicated page for Liminal Biosciences news (Ticker: LMNL), a resource for investors and traders seeking the latest updates and insights on Liminal Biosciences stock.

Liminal BioSciences Inc. (NASDAQ: LMNL) is a clinical-stage biopharmaceutical leader developing innovative therapies for unmet medical needs. This dedicated news hub provides timely updates on their small molecule therapeutics, plasma-derived treatments, and strategic business developments.

Investors and industry professionals will find essential information about clinical trial progress, regulatory milestones, and financial updates. Key focus areas include developments around Fezagepras for pulmonary fibrosis, Ryplazim for plasminogen deficiency, and the company's recent acquisition agreement signaling strategic growth.

Our curated news collection features press releases on pipeline advancements, partnership announcements, and financial disclosures. Regular updates ensure stakeholders stay informed about LMNL's work across metabolic, inflammatory, and fibrotic disease research.

Bookmark this page for direct access to verified updates from Liminal BioSciences. Check back frequently to monitor progress across their therapeutic platforms and corporate initiatives.

Rhea-AI Summary
Liminal BioSciences Inc. has completed a transaction with Structured Alpha LP, where SALP acquired all outstanding common shares of Liminal BioSciences at a price of US$8.50 per share. As a result, the shares will no longer be listed on the Nasdaq Capital Market, and Liminal BioSciences will cease to be a reporting issuer under Canadian securities law. The company is focused on developing small molecule therapeutics for metabolic, inflammatory, and fibrotic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Liminal BioSciences received final court order for plan of arrangement with Structured Alpha LP
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Liminal BioSciences shareholders approve plan of arrangement with Structured Alpha LP
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
none
Rhea-AI Summary
Liminal BioSciences files amended Schedule 13E-3 and supplement to the management information circular
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
none
-
Rhea-AI Summary
Liminal BioSciences Inc. has obtained an interim order from the Ontario Superior Court of Justice for a proposed arrangement with Structured Alpha LP. Under the arrangement, SALP will acquire all outstanding common shares of Liminal BioSciences not currently owned by SALP or its affiliates at a price of US$8.50 per share. The arrangement is subject to shareholder approval and the issuance of a final court order.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
none
-
Rhea-AI Summary
Liminal BioSciences Inc. (Nasdaq: LMNL) provided an R&D update on their GPCR-targeted pipeline, including the nomination of a lead candidate for the OXER1 antagonist program. They also reported their financial results for the second quarter ended June 30, 2023, with a net loss from continuing operations of CAD 9 million. The company closed June 30, 2023, with over CAD 19 million cash on hand, expecting to provide cash runway into December 2023. Additionally, they entered into an Arrangement Agreement with Structured Alpha LP, potentially providing minority shareholders US$8.50 in cash per Common Share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
Rhea-AI Summary
Liminal BioSciences Inc. and Structured Alpha LP have entered into an agreement under which SALP will acquire all of the issued and outstanding common shares of Liminal BioSciences. Liminal BioSciences shareholders will receive US$8.50 in cash per share, representing a premium of approximately 135% over the closing share price on Nasdaq on April 4, 2023. The transaction is expected to close no later than September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
40.71%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.19%
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.59%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
Liminal Biosciences Inc

Nasdaq:LMNL

LMNL Rankings

LMNL Stock Data

27.62M
1.26M
61.26%
0.77%
0.02%
Biotechnology
Healthcare
Link
Canada
Laval